Erasca shares sink after patient death in early-stage cancer drug trial [Yahoo! Finance Canada]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance Canada
its experimental cancer drug, ?even though analysts said the incident was unlikely to signal a broader safety ?issue. The San Diego-based company said a 66-year-old pancreatic cancer patient who had received its experimental drug, ERAS-0015, developed severe lung inflammation, known as pneumonitis, about a month after starting the treatment. The patient was treated ?aggressively with high-dose steroids and ?other medications, but later chose to withdraw supportive care and died. The company said it does not ?expect the event to be a broader concern. J.P. Morgan analyst Anupam Rama said it was "more of a one-off case versus a clear drug-related ?concern," noting ?the patient had pulmonary tumors ?and a history of a ?prior lung procedure. Analysts at Clear Street gave a similar opinion, saying the patient had withdrawn care before resolution. It also said the "management does not expect pneumonitis frequency to rise meaningfully with broader use." Even so, Evercore ISI analyst
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026GlobeNewswire
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges [Yahoo! Finance]Yahoo! Finance
- Revolution's on a pancreatic cancer winning streak. What comes next for the biotech? [Yahoo! Finance]Yahoo! Finance
- Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates [Yahoo! Finance]Yahoo! Finance
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug [FOX News]FOX News
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/29/26 - Form 4
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form ARS
- RVMD's page on the SEC website